Physician profile
Amanda Brooks
NPI 1902443039
$2,559.48
in general payments reported to CMS, 2019-2025
30 companies · $761 in 2025
The $761 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $888 · 2024: $761 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $420.84 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $413.72 | 2022-2025 | |
| Novo Nordisk INC | $178.63 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $157.87 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Phathom Pharmaceuticals, INC. | $141.28 | 2024-2025 | Voquezna |
| Amgen INC. | $135.93 | 2023-2025 | Repatha, Otezla, Otezla |
| Noven Therapeutics, LLC | $120.82 | 2024-2025 | Xelstrym |
| Axsome Therapeutics, INC. | $100.93 | 2023 | Auvelity |
| Glaxosmithkline, LLC. | $89.90 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.93 | 2023-2024 | Xifaxan, Trulance |
| Fresenius USA Marketing, INC. | $71.69 | 2024-2025 | Velphoro, Velphoro |
| Pfizer INC. | $69.50 | 2023 | |
| Idorsia Pharmaceuticals US INC | $67.19 | 2023-2024 | Quviviq |
| Biohaven Pharmaceutical Holding Company LTD. | $54.04 | 2022 | |
| Dexcom, INC. | $52.05 | 2022-2023 | Dexcom G6 Transmitter |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $50.14 | 2023-2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.50 | 2024-2025 | Jardiance, Synjardy |
| Novartis Pharmaceuticals Corporation | $40.56 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $38.37 | 2023-2024 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $31.82 | 2024 | Trintellix |
| Smith+Nephew, INC. | $31.52 | 2025 | Pico |
| Kowa Pharmaceuticals America, INC. | $27.29 | 2022-2025 | Zoryve |
| Seqirus USA INC | $24.22 | 2025 | Fluad |
| Bayer Healthcare Pharmaceuticals INC. | $23.00 | 2024 | |
| Medtronic, INC. | $21.08 | 2025 | In.Pact Admiral |
| Boston Scientific Corporation | $17.01 | 2024 | Xpeeda Dsl Fiber |
| Lundbeck LLC | $16.18 | 2025 | Rexulti |
| Currax Pharmaceuticals LLC | $14.65 | 2025 | Contrave |
| Merck Sharp & Dohme LLC | $14.11 | 2022 | |
| Exact Sciences Corporation | $13.71 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.